letosteine : A dicarboxylic acid monoester that is the monoethyl ester of 2-{2-[(carboxymethyl)sulfanyl]ethyl}-1,3-thiazolidine-4-carboxylic acid. A mucolytic used in the treatment of chronic bronchopneumopathies and related conditions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 68707 |
| CHEMBL ID | 2105044 |
| CHEBI ID | 88271 |
| SCHEMBL ID | 19562 |
| MeSH ID | M0070262 |
| Synonym |
|---|
| letosteine |
| viscotiol |
| viscotiol (tn) |
| D07380 |
| 53943-88-7 |
| letosteine (inn) |
| 2-[2-(2-ethoxy-2-oxoethyl)sulfanylethyl]-1,3-thiazolidine-4-carboxylic acid |
| CHEMBL2105044 |
| einecs 258-879-3 |
| letosteine [inn] |
| letosteinum [inn-latin] |
| letosteina [inn-spanish] |
| 2-(2-((carboxymethyl)thio)ethyl)-4-thiazolidinecarboxylic acid 2-ethyl ester |
| 6mvf9u95dw , |
| unii-6mvf9u95dw |
| letosteinum |
| 4-thiazolidinecarboxylic acid, 2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)- |
| letosteina |
| AKOS015893059 |
| letosteine [mi] |
| letosteine [mart.] |
| letosteine [who-dd] |
| MLS006010171 |
| smr004701279 |
| SCHEMBL19562 |
| KS-5194 |
| DB08939 |
| CHEBI:88271 |
| 2-{2-[(2-ethoxy-2-oxoethyl)sulfanyl]ethyl}-1,3-thiazolidine-4-carboxylic acid |
| BCP17027 |
| mfcd00867663 |
| 2-(2-((2-ethoxy-2-oxoethyl)thio)ethyl)thiazolidine-4-carboxylic acid |
| Q660090 |
| DTXSID70866372 |
| BRD-A32597168-001-01-0 |
| H10643 |
| A923520 |
| CS-0028204 |
| HY-107355 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Letosteine has been found to be effective in treating patients with chronic bronchopneumopathies in clinical practice. " | ( Development of a novel LC-MS/MS method for the determination of letosteine in human plasma and its application on pharmacokinetic studies. Cao, C; Chen, H; Liu, X; Qian, Z; Tang, W; Wang, J; Wen, X; Yuan, S; Zheng, H; Zhu, Y, 2011) | 2.05 |
A rapid and sensitive method based on liquid chromatography and tandem mass spectrometry (LC-MS/MS) was developed and validated for the analysis of letosteine in plasma samples.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Based on previous animal and on preliminary human results a further human study was performed in order to confirm the relevant pharmacokinetic parameters and the lack of accumulation of letosteine after repeated administrations." | ( Pharmacokinetic study of 14C-letosteine in man after oral intake and steady-state. Donath, A; Llull, JB; Schifflers, MH; Wermeille, M, 1991) | 0.76 |
| " To provide robust support for its pharmacokinetic and clinical studies, a rapid and sensitive method based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was developed and validated for the analysis of letosteine in plasma samples." | ( Development of a novel LC-MS/MS method for the determination of letosteine in human plasma and its application on pharmacokinetic studies. Cao, C; Chen, H; Liu, X; Qian, Z; Tang, W; Wang, J; Wen, X; Yuan, S; Zheng, H; Zhu, Y, 2011) | 0.79 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The results show a good absorption rate of letosteine since about 90% of the dose was found in the urine." | ( Pharmacokinetic study of 14C-letosteine in man after oral intake and steady-state. Donath, A; Llull, JB; Schifflers, MH; Wermeille, M, 1991) | 0.83 |
| Role | Description |
|---|---|
| mucolytic | A compound that alters the structure of mucus so as to decrease its viscosity and thereby facilitate its removal by ciliary action and expectoration. Compare with antitussives, which suppress the cough reflex, and expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dicarboxylic acid monoester | A monoester of a dicarboxylic acid. |
| thiazolidinemonocarboxylic acid | A thiazolidine or thiazolidine derivative carrying a single carboxy substituent. |
| aliphatic sulfide | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.03) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (64.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (35.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||